Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323582 | 0.89 | DYRK1A (0.48) | DYRK1ADYRK1BTP53LMNASMN1; SMN2 | |
| SCHEMBL10324083 | 0.88 | DYRK1A (0.64) | DYRK1ADYRK1BTP53LMNASMN1; SMN2 | |
| SCHEMBL10323719 | 0.85 | DYRK1A (0.49) | DYRK1ADYRK1BLMNASMN1; SMN2MAPK1 | |
| SCHEMBL10323240 | 0.84 | DYRK1A (0.47) | DYRK1ADYRK1BTP53LMNASMN1; SMN2 | |
| SCHEMBL11950582 | 0.82 | DYRK1A (0.63) | DYRK1ADYRK1B | |
| SCHEMBL11304261 | 0.79 | DYRK1A (0.49) | DYRK1ADYRK1BTP53 | |
| SCHEMBL10324514 | 0.79 | DYRK1A (0.49) | DYRK1ADYRK1BTP53LMNA | |
| SCHEMBL10446982 | 0.78 | DYRK1A (0.66) | DYRK1ADYRK1B | |
| SCHEMBL10323580 | 0.77 | DYRK1A (0.67) | DYRK1ADYRK1BSMN1; SMN2HTTNPSR1 | |
| SCHEMBL10324226 | 0.74 | PTPN11 (0.43) | DYRK1ADYRK1BSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DYRK1A 654/4885DYRK1B 570/4885TP53 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.